bdnf cognitive comparison

Semax vs Selank: The Russian Nootropic Stack That Balances Focus and Calm

April 22, 2026 · Updated May 17, 2026

Semax and Selank are the two most-studied nootropic peptides to come out of Russian research — and they do completely different jobs. Semax is the focus engine, built on the ACTH(4-10) fragment to drive BDNF and neuroplasticity. Selank is the calm switch, built on tuftsin to dampen anxiety through GABAergic gene expression without sedation. Researchers pair them because each compound covers the other's blind spot.

The Quick Read

Semax → BDNF upregulation, cognitive drive, neuroplasticity. The closest thing to a non-stimulant focus peptide in published research.
Selank → GABAergic anxiolysis without sedation. The closest thing to a non-benzodiazepine calm peptide in published research.
Together → cognition under stress. Semax sharpens, Selank settles. Neither compromises the other's mechanism.
Both → >=99.5% HPLC-verified at Ki. Research use only.

Why this comparison matters

Most nootropic research forces a trade-off. Stimulant-class compounds amplify focus and anxiety together — you end up wired but unable to concentrate. Benzodiazepine-class compounds calm anxiety at the cost of cognition. The Semax + Selank pair solves both failure modes at once by splitting the jobs across two compounds with non-overlapping mechanisms.

Pick the wrong one and you are answering a different question than the one you wrote down. The point of this article is to make the choice obvious — and to explain why researchers usually end up running both.

What Is Semax?

Semax is a synthetic heptapeptide built on the neurotrophic core of ACTH. Sequence: Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues are ACTH(4-7), the portion of adrenocorticotropic hormone that carries the cognitive activity without the adrenal-stimulating hormonal effects. The C-terminal Pro-Gly-Pro extension is a stability hack — it resists aminopeptidase degradation in the CNS, extending the biological half-life dramatically.

Molecular weight: 813.9 Da. Small enough to cross the blood-brain barrier efficiently via olfactory and trigeminal nerve pathways.

Semax's headline effect is the magnitude of its BDNF upregulation. Dolotov et al. (2006), published in Brain Research, documented 3-8-fold increases in BDNF mRNA expression in the hippocampus and cortex within hours of administration. That is not a subtle neurotrophic signal. It is one of the most potent pharmacological BDNF inducers identified in the literature.

BDNF is the master neurotrophin for learning, memory, synaptic plasticity, and long-term potentiation. That is why Semax's cognitive effects in research models look more like structural neuroplasticity than stimulant-style neurotransmitter manipulation.

Molecular weight: 813.9 Da | Purity: >=99.5% HPLC-verified | View Semax 10mg

What Is Selank?

Selank is a synthetic heptapeptide built on the tuftsin tetrapeptide, an endogenous immune-regulatory fragment of IgG. Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues are tuftsin itself, naturally cleaved from the Fc region of IgG. Same Pro-Gly-Pro stability extension as Semax, for the same reason: extended CNS half-life.

Molecular weight: 751.9 Da.

Selank's design objective was narrow and specific — build an anxiolytic that works through the GABAergic system but does not produce the sedation, cognitive impairment, tolerance, or dependence that benzodiazepines produce. The mechanism is unusual: rather than acutely potentiating existing GABA-A receptors the way benzodiazepines do, Selank reshapes the GABAergic landscape at the genomic level. Volkova et al. (2016), published in Frontiers in Pharmacology, found that Selank influences the expression of 84+ genes related to GABAergic signaling, including GABA-A receptor subunit genes.

The result: anxiolysis without the cognitive trade-off. No allosteric receptor binding. No tolerance loop. No withdrawal.

Molecular weight: 751.9 Da | Purity: >=99.5% HPLC-verified | View Selank 10mg

Mechanism: where they diverge

The easiest way to see the difference is to look at the receptor targets.

Semax targets: - BDNF / TrkB receptor upregulation (the primary mechanism) - Melanocortin MC3 / MC4 receptors (attention and motivation) - Serotonergic and dopaminergic tone (mood stability alongside cognition) - Does not engage the HPA axis, does not raise cortisol

Selank targets: - GABA-A receptor subunit expression and sensitivity (the primary mechanism) - Enkephalin degradation inhibition (mood regulation via endogenous opioid peptides) - Inflammatory cytokine modulation — particularly IL-6 — via the tuftsin pathway - Does not bind the benzodiazepine allosteric site, does not produce tolerance

Semax pushes neurons toward growth and plasticity. Selank tunes the inhibitory/excitatory balance and the neuroimmune axis. Different systems. Different leverage points. They can operate on the same brain at the same time without fighting each other.

Head-to-Head Comparison

Feature	Semax	Selank
Parent molecule	ACTH(4-10) fragment	Tuftsin (IgG-derived tetrapeptide)
Sequence	Met-Glu-His-Phe-Pro-Gly-Pro	Thr-Lys-Pro-Arg-Pro-Gly-Pro
Primary mechanism	BDNF / TrkB upregulation	GABA-A subunit expression modulation
Secondary mechanisms	Melanocortin, serotonergic, dopaminergic	Enkephalinase inhibition, IL-6 modulation
Effect profile	Focus, memory, neuroplasticity, drive	Calm, anxiety reduction, mood stability
Sedating?	No	No
Hormonal effects?	None (HPA axis not engaged)	None
Tolerance risk	Low (genomic mechanism)	Low (genomic mechanism)
Immune activity	Limited	Significant (tuftsin lineage)
Regulatory status	Approved nootropic in Russia	Approved anxiolytic in Russia
Best-studied endpoint	BDNF upregulation, cognitive performance	Anxiolysis without cognitive compromise

The Published Research

Semax: the BDNF engine

Dolotov et al. (2006), Brain Research. Semax administration produced a 3-8-fold increase in BDNF mRNA in the hippocampus and cortex within hours. This is the citation that defines Semax's neurotrophic reputation.

Eremin et al. (2005), Neurochemical Research. Semax modulated dopamine and serotonin turnover in the striatum and hippocampus — without engaging the HPA axis. This confirmed Semax's multi-pathway nootropic mechanism extends beyond BDNF to monoamine systems, while still avoiding the cortisol-releasing activity of its parent molecule.

Medvedeva et al. (2013), BMC Genomics. Semax altered expression of 80+ genes in ischemic brain tissue, producing measurable neuroprotection and reduced neuronal death in stroke models. This is part of why Semax appears in the neuroprotection literature, not just the cognition literature.

Kaplan et al. (2009), Russian clinical literature. Cognitive disorder patients treated with Semax showed improved executive function, attention, and memory scores — the human clinical data that supports its regulatory status as a nootropic.

Selank: the anxiolysis-without-sedation engine

Zozulya et al. (2008), Bulletin of Experimental Biology and Medicine. Selank significantly inhibited the enzymatic degradation of enkephalins in blood serum. This is the mechanistic basis for Selank's mood-stabilizing activity — by prolonging endogenous enkephalin activity, it amplifies the body's own opioid-peptide tone without introducing exogenous opioid activity.

Volkova et al. (2016), Frontiers in Pharmacology. Selank influenced expression of 84+ genes related to GABAergic signaling, including GABA-A receptor subunit composition. This is the clearest evidence that Selank's anxiolytic mechanism operates at the genomic level — reshaping how GABAergic neurons are configured rather than forcing activation of existing receptors.

Uchakina et al. (2008), Bulletin of Experimental Biology and Medicine. Selank normalized IL-6 and other inflammatory cytokine levels in anxious patients while simultaneously reducing anxiety scores. This is the clinical evidence for Selank's dual anxiolytic-immunomodulatory profile — directly relevant to the growing research literature on neuroinflammation and anxiety.

Kozlovskii & Danchev (2003), Neuroscience and Behavioral Physiology. Selank produced anxiolytic effects comparable to benzodiazepines in behavioral avoidance models — without impairing learning or producing sedation. This is the study that distinguishes Selank's profile from traditional GABAergic anxiolytics.

Why Stack Them Together?

The stack works because the two peptides are mechanistically non-overlapping. Semax drives up neuroplasticity and cognitive drive. Selank calms the GABAergic background and reduces the inflammatory and stress tone that would otherwise compete with that cognitive work.

Coverage, not overlap

A purely activating nootropic amplifies anxiety along with focus — you end up wired but unable to concentrate. A purely calming compound does the reverse: anxiolysis at the cost of cognition. The Semax + Selank stack addresses both failure modes by splitting the two jobs across two compounds with different mechanisms.

Semax handles: focus, working memory, learning, neuroplasticity, drive.
Selank handles: anxiety, stress resilience, mood stability, neuroinflammation.

Neither peptide compromises the other's mechanism.

Shared engineering pedigree

Both compounds share the Pro-Gly-Pro C-terminal stability extension. Both cross the blood-brain barrier efficiently. Both have comparable CNS pharmacokinetic profiles. Neither engages the HPA axis. Neither produces hormonal confounders. Neither produces tolerance in the way traditional monoamine-modulating nootropics eventually do.

For researchers designing cognitive neuroscience protocols, that shared clean profile is a significant advantage. The two peptides stack without introducing incompatible variables.

Psychoneuroimmunology coverage

Selank's IL-6 modulation is increasingly relevant to research on the inflammatory model of anxiety and depression. When stacked with Semax — which has its own neuroprotective and anti-inflammatory activity in stroke models (Medvedeva et al., 2013) — the pair covers both the neuroimmune and neurotrophic axes simultaneously. For research at the intersection of cognition, mood, and inflammation, this is a single tool that touches multiple relevant pathways.

Research Applications Where the Stack Is the Default

Cognitive performance under stress. Laboratory and naturalistic stress paradigms compromise cognitive performance via cortisol and neuroinflammatory effects. The stack addresses both sides: Semax supports the cognition, Selank damps the stress response. For cognition-under-pressure paradigms, this removes confounders that single-peptide protocols leave in place.

Neuroplasticity + mood research. Learning and memory research often produces mood-state confounders — repeated cognitive tasks can produce anxiety that degrades performance. The stack lets researchers isolate cognitive endpoints by stabilizing mood without sedating the subject.

Peptide alternatives to stimulant + benzodiazepine polypharmacy. Traditional research polypharmacy (stimulant + benzodiazepine) introduces cortisol elevation, tolerance, and cognitive blunting variables. The Semax + Selank stack covers the same functional space — activation + calm — through peptide mechanisms that do not produce those confounders.

Neuroprotection research. Semax's neuroprotective effects in ischemic models (Medvedeva et al., 2013) pair with Selank's neuroinflammatory modulation (Uchakina et al., 2008) to give researchers a two-compound stack that addresses both the direct neuronal injury response and the downstream neuroinflammatory cascade.

Which One If You Can Only Study One?

The choice depends on the research question.

Choose Semax if the primary endpoints are cognitive performance, neuroplasticity, BDNF signaling, or neuroprotection. Semax is the stronger pick whenever the question is about building cognitive capacity — synaptic density, long-term potentiation, working memory, learning rate. Age-related cognitive decline, ischemic neuroprotection, BDNF pathway pharmacology — Semax first.

Choose Selank if the primary endpoints are anxiolysis without cognitive impairment, GABAergic receptor biology, psychoneuroimmunology, or non-sedating anxiety research. Selank is the stronger pick whenever the question is about removing the stress and anxiety confounders without introducing the cognitive costs of benzodiazepine-class compounds.

Choose both if the research design benefits from covering cognition and anxiety simultaneously, or if the study population involves stress-impacted cognitive performance. This is the default stack for cognitive research programs.

Stack Design Considerations

CNS bioavailability

Both peptides have favorable CNS pharmacokinetic profiles — small enough to cross the blood-brain barrier efficiently, stabilized by their Pro-Gly-Pro extensions against aminopeptidase degradation. Pharmacokinetic data for multiple research paradigms is available across the referenced primary literature.

Timing relative to task demand

Semax's BDNF mRNA peak is observed within hours of administration (Dolotov et al., 2006). Selank's anxiolytic effects develop over a similar time course but operate through a different mechanism (genomic modulation of GABAergic signaling). Research protocols that need both cognitive enhancement and anxiolysis during a specific task window typically align both compounds to the same pre-task timing.

Other stack partners

Semax and Selank both pair cleanly with longevity peptides in cognitive aging research. Common extensions: pairing with NAD+ for mitochondrial brain energy support, with GHK-Cu for broader neuroprotection and gene-expression modulation (see GHK-Cu: The Copper Peptide That Resets 4,000 Genes), or with Epitalon for telomere maintenance research in aging-brain models (see Epitalon & Telomerase: The 4-Amino-Acid Longevity Peptide).

Purity and Research-Grade Sourcing

Nootropic research is particularly unforgiving of low-purity material. Truncated sequences and synthesis contaminants do not cleanly map onto the BDNF or GABAergic pathways the way the intact compounds do — they introduce noise into behavioral and molecular endpoints. Both Semax and Selank from Ki Peptides are HPLC-verified at >=99.5% purity, third-party tested, with batch-specific documentation. For the detailed rationale on why >=99% purity matters, see Peptide Purity: Why >=99% Matters.

Frequently Asked Questions

Are Semax and Selank the same thing?

No. They share an institutional origin (Russian Academy of Sciences, 1990s), a similar structural format (heptapeptides with Pro-Gly-Pro stability extensions), and both crossed into regulatory-approved clinical use in Russia. But they are built on completely different parent molecules (ACTH(4-10) vs tuftsin) and target completely different primary mechanisms (BDNF/TrkB vs GABAergic subunit expression). Semax is a nootropic; Selank is an anxiolytic. They are complementary, not redundant.

Which one should I start research with?

If the research question is cognitive performance, neuroplasticity, or neuroprotection, start with Semax. If the research question is anxiolysis without cognitive impairment or psychoneuroimmunology, start with Selank. If the research question involves cognitive performance under stress or mood-stable neuroscience endpoints, the stack is the default.

Do Semax and Selank produce tolerance like stimulants or benzodiazepines?

Neither compound produces the classical tolerance or dependence associated with direct neurotransmitter modulators. Semax operates through gene expression changes (BDNF / TrkB upregulation, melanocortin modulation) rather than direct monoamine receptor occupancy — so it does not drive the receptor downregulation that produces stimulant tolerance. Selank operates through GABA-A subunit expression changes rather than direct benzodiazepine-site binding — so it does not drive the receptor desensitization that produces benzodiazepine tolerance and withdrawal. Both mechanisms are genomic rather than acute-pharmacologic, which is why research studies consistently show preserved efficacy across repeated administration.

Does Semax engage the HPA axis because it is derived from ACTH?

No. This is the whole point of the ACTH(4-10) fragment design. Semax retains the neurotrophic activity of ACTH while eliminating the hormonal activity. The MC2 receptor — the receptor responsible for ACTH's adrenal cortisol-releasing activity — is not activated by the ACTH(4-10) fragment. Semax does not raise cortisol, does not stimulate the adrenals, and does not engage the HPA axis. This was a deliberate design objective of its development at the Russian Academy of Sciences.

Does Selank cause sedation or cognitive impairment like benzodiazepines?

No. This is Selank's core differentiator from benzodiazepines. Benzodiazepines directly potentiate existing GABA-A receptors at the allosteric binding site, producing anxiolysis along with sedation, cognitive dulling, tolerance, and dependence. Selank modulates GABA-A subunit expression at the genomic level — it reshapes the GABAergic system over time rather than acutely forcing receptor activation. Kozlovskii & Danchev (2003) demonstrated anxiolytic effects comparable to benzodiazepines in rodent behavioral models without impairing learning or producing sedation. Human clinical data from Russian regulatory trials confirmed the same cognitive-sparing profile.

Can Semax and Selank be stacked with longevity peptides?

Yes. Common research stacks include Semax + Selank + NAD+ for cognitive support plus mitochondrial brain energy, Semax + Selank + GHK-Cu for cognitive support plus broad neuroprotection, and Semax + Selank + Epitalon for cognitive support plus telomere maintenance in aging-brain research models. None of these longevity compounds produce pharmacodynamic conflicts with the Semax or Selank mechanisms.

Are these peptides for human therapeutic use in the United States?

No. While Semax and Selank are approved as prescription medications in Russia, they are sold in the United States and internationally strictly as research peptides for preclinical and in vitro investigation. Neither is FDA-approved for human therapeutic use in the United States. Published clinical research from Russia is cited here for its scientific content, not as a regulatory basis for use outside of Russia. Ki Peptides products are intended for research use only.

Sources

Dolotov, O.V., Seredenina, T.S., Levitskaya, N.G., Kamensky, A.A., Andreeva, L.A., Alfeeva, L.Y., et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54-60.
Eremin, K.O., Kudrin, V.S., Saransaari, P., Oja, S.S., Grivennikov, I.A., Myasoedov, N.F., & Rayevsky, K.S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493-1500.
Medvedeva, E.V., Dmitrieva, V.G., Povarova, O.V., Limborska, S.A., Skvortsova, V.I., Myasoedov, N.F., & Dergunova, L.V. (2013). The neuropeptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia. BMC Genomics, 14, Suppl 3.
Volkova, A., Shadrina, M., Kolomin, T., Andreeva, L., Limborska, S., Myasoedov, N., & Slominsky, P. (2016). Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Frontiers in Pharmacology, 7, 31.
Zozulya, A.A., Neznamov, G.G., Siuniakov, T.S., Kost, N.V., Gabaeva, M.V., Serebriakova, E.V., et al. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic drug Selank in the therapy of generalized anxiety disorders and neurasthenia. Bulletin of Experimental Biology and Medicine, 146(3), 288-290.
Uchakina, O.N., Uchakin, P.N., Miasoedov, N.F., Andreeva, L.A., Shcherbenko, V.E., Mezentseva, M.V., et al. (2008). Immunomodulatory effects of Selank in patients with anxiety-asthenic disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 108(5), 71-75.
Kozlovskii, I.I., & Danchev, N.D. (2003). The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neuroscience and Behavioral Physiology, 33(7), 639-643.
Kaplan, A.Y., Kochetova, A.G., Nezavibathko, V.N., Ryasina, T.V., Ashmarin, I.P. (1996). Synthetic ACTH analogue Semax displays nootropic-like activity in humans. Neuroscience Research Communications, 19(2), 115-123.
Myasoedov, N.F., Andreeva, L.A., Grivennikov, I.A., Dolotov, O.V., Kamensky, A.A., Levitskaya, N.G., et al. (1999). Investigation of mechanisms of neuroprotective action of Semax in experimental stroke. Journal of Higher Nervous Activity, 49(5), 774-783.

All compounds referenced are sold strictly for research use only. Ki Peptides does not sell products for human consumption, and no statements on this page have been evaluated by the FDA. Consult applicable regulations in your jurisdiction before purchasing.